Keyphrases
Psoriasis
100%
Mycosis Fungoides
36%
Biological Treatment
30%
Moderate-to-severe Psoriasis
27%
Ixekizumab
24%
Secukinumab
23%
Psoriasis Disease
17%
Drug Survival
17%
Scalp
16%
Risankizumab
15%
Psoriatic Arthritis
14%
Tertiary Care Hospital
13%
Ustekinumab
13%
Biologic Therapy
13%
Adalimumab
12%
Biological Drugs
12%
Generalized Pustular Psoriasis
12%
Psoriasis Severity
11%
Etanercept
11%
Israeli
11%
Methotrexate
10%
Hidradenitis Suppurativa
10%
Cutaneous T-cell Lymphoma
10%
Pediatric Psoriasis
10%
Single-center Experience
10%
Inflammatory Bowel Disease
10%
Atopic Dermatitis
10%
Skin Eruption
10%
Suboptimal Response
10%
Static Physician's Global Assessment
9%
Retrospective Cohort Study
9%
Severity Index
9%
Psoriasis Area
9%
Area Index
9%
Systemic Treatment
8%
Glutamatergic Transmission
8%
Psychological Stress
8%
Stress-induced
8%
Dermatology Life Quality Index
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
Confidence Interval
7%
Psoriasis Treatment
7%
TNF Inhibitors
7%
Ultraviolet-B (UV-B)
7%
Skin Diseases
7%
Clinical Data
6%
Biological Agents
6%
Anti-TNF Agents
6%
Human Leukocyte Antigen System
6%
IL-17 Inhibitors
6%
Medicine and Dentistry
Psoriasis
65%
Mycosis fungoides
36%
Dermatology
21%
Pediatrics
18%
TNF Inhibitor
18%
Ixekizumab
17%
Systematic Review
16%
Secukinumab
16%
Risankizumab
15%
Biological Product
15%
Phototherapy
14%
Scalp
13%
Systemic Therapy
12%
Psoriasis Vulgaris
11%
Exanthem
11%
Generalized Pustular Psoriasis
11%
Diseases
11%
Cutaneous T Cell Lymphoma
10%
Atopic Dermatitis
10%
Patient with Inflammatory Bowel Disease
10%
Arm
10%
Pediatrics Patient
10%
Methotrexate
9%
Adalimumab
9%
Alopecia Mucinosa
9%
Biological Therapy
9%
Nail
9%
Adverse Event
8%
Ustekinumab
8%
Dermatology Life Quality Index
7%
Comorbidity
7%
Interleukin 17
7%
Psoriatic Arthritis
7%
Skin Disease
7%
Dermatitis
7%
Patient Referral
7%
Inflammatory Bowel Disease
6%
Melanoma
6%
Dermatosis
5%
Skin Surgery
5%
Human Leukocyte Antigen
5%
Skin Cancer
5%
CD8 Antigen
5%
Demodicosis
5%
Prurigo
5%
Papular Rash
5%
Pemphigus
5%
Psoralen
5%
Vitiligo
5%
Medical Decision Making
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
87%
Biological Product
23%
Tumor Necrosis Factor Inhibitor
19%
Psoriatic Arthritis
13%
Diseases
12%
Ixekizumab
12%
Secukinumab
12%
Ustekinumab
11%
Inflammatory Bowel Disease
10%
Risankizumab
10%
Rash
10%
Interleukin 17
9%
Methotrexate
8%
Cohort Study
8%
Alopecia
8%
Etanercept
7%
Psoriasis Vulgaris
6%
Guselkumab
6%
Retrospective Study
5%
Infection
5%
Prevalence
5%
Hepatitis B Virus
5%
Observational Study
5%
Apremilast
5%
Alexithymia
5%
Suppurative Hidradenitis
5%
Cytokine
5%
Hyperthyroidism
5%
Hepatitis C Virus
5%
Hypothyroidism
5%
Vismodegib
5%
Basal Cell Carcinoma
5%
Phase IV
5%
Atopic Dermatitis
5%
Mycosis fungoides
5%
Cardiovascular Risk
5%
Systemic Treatment
5%